Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GLAXOSMITHKLINE : Credit Suisse remains Neutral

10/29/2020 | 07:32am EST

Analyst Trung Huynh from Credit Suisse research gives the stock a Neutral rating. The target price is unchanged and still at GBX 1580.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
CREDIT SUISSE GROUP AG 0.21% 11.665 Delayed Quote.-11.18%
GLAXOSMITHKLINE PLC 0.91% 1393.6 Delayed Quote.-22.37%
All news about GLAXOSMITHKLINE PLC
12/01U.S. plans for first COVID vaccines as pandemic deaths surge again
RE
12/01ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions..
AQ
12/01GLAXOSMITHKLINE : ViiV Healthcare and the Medicines Patent Pool expand access to..
AQ
11/26French health minister confirms vaccination could start by end of year
RE
11/25How will Canada's COVID-19 vaccine program work?
RE
11/25EXPLAINER : When and how will COVID-19 vaccines become available?
RE
11/24AstraZeneca Gears Up to Vaccinate the World Against Covid-19
DJ
11/23GLAXOSMITHKLINE : GSK starts phase 3 study of RSV maternal candidate vaccine
AQ
11/23GLAXOSMITHKLINE : GSK starts phase 3 study of RSV maternal candidate vaccine
PU
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
DJ
More news
Financials
Sales 2020 34 219 M 45 706 M 45 706 M
Net income 2020 4 855 M 6 485 M 6 485 M
Net Debt 2020 22 921 M 30 615 M 30 615 M
P/E ratio 2020 14,2x
Yield 2020 5,74%
Capitalization 69 370 M 92 552 M 92 657 M
EV / Sales 2020 2,70x
EV / Sales 2021 2,56x
Nbr of Employees 99 437
Free-Float 92,3%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 1 712,02 GBX
Last Close Price 13,94 GBX
Spread / Highest target 16 763%
Spread / Average Target 12 185%
Spread / Lowest Target 7 832%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-22.37%92 309
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415